Log In
Print
BCIQ
Print
Print this Print this
 

Extina, ketoconazole

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionFoam formulation of 2% ketoconazole
Molecular Target Cytochrome P450 C-14 alpha demethylase (CYP51)
Mechanism of ActionCytochrome P450 C-14 alpha demethylase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDermatitis
Indication DetailsTreat seborrheic dermatitis; Treat seborrheic dermatitis fungal infections
Regulatory Designation
Partner Renaissance Acquisition Holdings LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today